Cutting Edge: Heat Shock Protein (HSP) 60 Activates the Innate Immune Response: CD14 Is an Essential Receptor for HSP60 Activation of Mononuclear Cells

Amir Kol, Andrew H. Lichtman, Robert W. Finberg, Peter Libby and Evelyn A. Kurt-Jones

http://www.jimmunol.org/content/164/1/13

**References**
This article cites 42 articles, 25 of which you can access for free at:
http://www.jimmunol.org/content/164/1/13.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Heat shock proteins (HSP), highly conserved across species, are generally viewed as intracellular proteins thought to serve protective functions against infection and cellular stress. Recently, we have reported the surprising finding that human and chlamydial HSP60, both present in human atheroma, can activate vascular cells and macrophages. However, the transmembrane signaling pathways by which extracellular HSP60 may activate cells remains unclear. CD14, the monocyte receptor for LPS, binds numerous microbial products and can mediate activation of monocytes/macrophages and endothelial cells, thus promoting the innate immune response. We show here that human HSP60 activates human PBMC and monocyte-derived macrophages through CD14 signaling and p38 mitogen-activated protein kinase, sharing this pathway with bacterial LPS. These findings provide further insight into the molecular mechanisms by which extracellular HSP may participate in atherosclerosis and other inflammatory disorders by activating the innate immune response. The Journal of Immunology, 2000, 164: 13–17.

Here is increasing interest in the role of nontraditional mediators of inflammation in atherosclerosis (1). Recent studies from our laboratory have shown that chlamydial and human heat shock protein 60 (HSP60) colocalize in human atheroma (2), and either HSP60 induces adhesion molecule and cytokine production by human vascular cells and macrophages, in a pattern similar to that induced by Escherichia coli LPS (3, 4). These results suggested that HSP60 and LPS might share similar signaling mechanisms. CD14 is the major high-affinity receptor for bacterial LPS on the cell membrane of mononuclear cells and macrophages (5, 6). In addition to LPS, CD14 functions as a signaling receptor for other microbial products, including peptidoglycan from Gram-positive bacteria and mycobacterial lipoarabinomann (7, 8). CD14 is considered a pattern recognition receptor for microbial Ags and, with Toll-like receptor (TLR) proteins, an important mediator of innate immune responses to infection (9–14). We have examined the role of CD14 in the response of human monocytes and macrophages to HSP60.

Materials and Methods

Reagents

Recombinant human HSP60 was purchased from StressGen Biotechnologies Corporation (Victoria, BC, Canada). E. coli LPS, PMA, and polymyxin B were purchased from Sigma (St. Louis, MO). CD14-blocking mAb (clone MY4) was purchased from Coulter Immunology (Hialeah, FL). Recombinant chlamydial HSP60 was purified as previously described (3) and passed over a commercial endotoxin removal cartridge (Endo-X, Associates of Cape Cod, Wood’s Hole, MA) following the manufacturer directions. Endotoxin levels were determined using a BioWhittaker Limulus amebocyte lysate assay kit (Walkersville, MD) and resistance to heat-treatment (100°C, 20 min). Different preparations of purified chlamydial HSP60 varied in their endotoxin content and heat resistance. In our previous studies, the macrophage-stimulating activity of the purified chlamydial HSP60 was completely heat labile (3). The preparation used in these studies was partially heat-resistant before removing residual endotoxin.

Cell culture and analysis of conditioned medium

PBMC were isolated from leukopacks of healthy donors by gradient centrifugation, and human macrophages were subsequently isolated by adherence and culture in 2% human serum for 10 days, as previously described (3). Human astrocytoma cells (U373 MG) stably transfected with human CD14 cDNA (U373-CD14) and control U373 cells were provided by Dr. Douglas Golenbock (Boston University Medical Center) (15). Culture supernatants were harvested 18–24 h after stimulation, and IL-6 secretion was determined by sandwich ELISA (Endogen, Cambridge, MA). Data are expressed as the mean ± SD of duplicate determination and are representative of 8–10 separate experiments for each cell type.

p38 mitogen-activated protein kinase (MAPK) assay

The activation of p38 MAPK was determined using an assay kit (New England Biolabs, Beverly, MA). Briefly, dually phosphorylated p38 MAPK was immunoprecipitated from cell lysates and subjected to in vitro
kinase assay with activating transcription factor 2 (ATF-2) as a kinase substrate. ATF-2 phosphorylation was determined by SDS-PAGE and Western blot analysis of the in vitro kinase reaction using a phospho-ATF-2-specific Ab.

**NF-κB activation in transfected hamster cells**

Chinese hamster ovary (CHO) cells stably transfected with human CD14 and a reporter plasmid (NF-κB response element of the E-selectin promoter fused to the coding region of the human CD25 gene) were provided by Dr. Douglas Golenbock (16). NF-κB activation was measured by flow cytometric analysis of cells stained with anti-CD25 mAb (Coulter Immunology) or polymyxin B (10 μg/ml) (Sigma) for 1 h before the addition of stimulant. In the indicated cultures, HSP60, LPS, and PMA were heat treated (100°C, 20 min) before addition to PBMC.

**Results**

**Human HSP60 stimulation of cytokine synthesis is CD14 dependent and not due to endotoxin**

We tested the hypothesis that HSP60 activates mononuclear cells and macrophages through CD14 signaling. As a measure of cellular activation, we assessed the cellular production of IL-6, an important proinflammatory cytokine and mediator of the acute-phase response (18).

Human HSP60 induced the synthesis of IL-6 by PBMC (Fig. 1A). HSP60 induced IL-6 similarly to optimal concentrations of E. coli LPS (Fig. 1B). Preincubation of PBMC with an anti-CD14 Ab blocked IL-6 production in response to either HSP60 or E. coli LPS. PMA also induced IL-6 production, but the anti-CD14 Ab inhibited IL-6 production in response to either HSP60 or E. coli LPS, but not to PMA (upper panels).

The recombinant HSP60 used in this study was purified from a fusion protein expressed in E. coli (19). Endotoxin levels were measured by Limulus ameobicocyte lysate assay (BioWhittaker). No endotoxin was detectable in the recombinant human HSP60. To further exclude possible endotoxin contamination, HSP60 and E. coli LPS samples were heat treated (100°C, 20 min) before incubation with cells. Heat treatment abolished the ability of HSP60 to induce IL-6 (Fig. 1A), but, as expected, it did not affect the stimulation of IL-6 production by LPS (Fig. 1B), thus suggesting that the observed activity of the HSP60 was not due to endotoxin contamination. This result was verified by stimulating PBMC with HSP60 or E. coli LPS in the presence of polymyxin B, which blocks LPS-induced cellular activation (20). Polymyxin B abolished the PBMC response to LPS (Fig. 1B), but had no effect on the response of PBMC to HSP60 (Fig. 1A). Quantitatively and qualitatively similar results were obtained when we examined the response of monocyte-derived macrophages (not shown).

The results obtained with blocking studies suggest that CD14 is critical to the activation of human monocytes/macrophages by HSP60. To confirm this interpretation, we examined the role of CD14 in the response to HSP60 using a human astrocytoma cell line, U373. U373 cells constitutively lack responsiveness to LPS, but acquire this property when stably transfected with a human CD14 cDNA (U373-CD14) (15) or when cultured in the presence of recombinant soluble CD14 (7, 21). Nontransfected U373 responded to neither HSP60 nor E. coli LPS, but were activated by PMA (Fig. 2, upper panels). U373 cells transfected with CD14 acquired the ability to produce IL-6 when exposed to either HSP60 or E. coli LPS (Fig. 2, lower panels). The anti-CD14 Ab inhibited only the responses to HSP60 and to E. coli LPS, but not to PMA (Fig. 2, upper and lower panels), supporting the role of CD14 as a crucial receptor for HSP60 on mononuclear phagocytes.

**Human HSP60 stimulates p38 MAPK activation**

We further examined the intracellular activation pathways used by HSP60. The CD14-dependent activation of human monocytes induced by LPS involves the dual phosphorylation and activation of p38 MAPK (22). PBMC were treated with either HSP60 or E. coli LPS, and p38 MAPK activation was determined by immunoprecipitation of dual-phosphorylated p38 and in vitro kinase assay measuring phosphorylation of the p38 substrate, ATF-2. Kinetic
We examined the ability of human and chlamydial HSP60 to activate NF-κB in reporter cell lines. Transfection with human CD14 is sufficient to confer LPS responsiveness on CHO cells detected by increased CD25 expression measured by flow cytometry (Fig. 5) (16, 17). Human HSP60 and chlamydial HSP60 did not induce CD25 expression in the reporter cell line, although the cells were responsive to LPS (Fig. 5). This is in contrast to our results with transfected U373 cells (Fig. 3), where transfection with CD14 is sufficient to confer responsiveness to HSP60. Thus, CD14 expression in a human (U373) but not a rodent (CHO) cell line is sufficient to confer HSP60 responsiveness, suggesting that additional coreceptor proteins are required for HSP60 signaling in hamster cells. These experiments also demonstrate that the requirements for responses to LPS and HSP60 are distinct and that the activity of the recombinant HSP60 proteins is not due to endotoxin.

Discussion

Recent studies from our laboratories and others have shown that HSP stimulate the production of cytokines from mononuclear cells (2, 3, 24–27). Both mammalian and bacterial HSP induced secretion of TNF-α and IL-6 (2, 3, 24, 25, 27). Our results show that CD14 signaling plays a fundamental role in mediating the activation of mononuclear cells and macrophages in response to human and chlamydial HSP60. (In contrast, E. coli groEL and Mycobacterium tuberculosis hsp65 stimulate monocytes in a CD14-independent manner (24, 28)). CD14 is a GPI-anchored membrane protein and, as such, it lacks a cytoplasmic domain (29). The mechanisms by which the signal mediated by CD14 is transduced across the cell membrane are not completely clear at present. Recent studies from our laboratory have suggested that the GPI-anchored CD14 is physically and functionally linked to heterotrimetric G proteins and src kinases in specialized glycolipid membrane microdomains (15).

Our studies with human CD14-transfected U373 (human) and CHO (hamster) cells demonstrate that CD14 is necessary but not sufficient for cellular responsiveness to HSP60, suggesting that human but not hamster cells express an important coreceptor for HSP60 signaling. TLRs have recently been shown to be important components of the CD14 signaling complex. TLRs are transmembrane proteins that contain large extracellular leucine-rich domains and intracellular domains that are homologous to the intracellular domain of the IL-1 receptor (12, 30). TLR2 and TLR4 have both been shown to contribute to the LPS response of human cells (9,
human CD14 and NF-κB using a CHO cell reporter line. These CHO cells are stably transfected with inflammatory and possibly activate the innate immune system. Pre-

microbial infections. Because both microbes and stressed or in-


Med. 188:2091.


Pugin, J., I. D. Heumann, A. Tomasz, V. V. Kravchenko, Y. Akamatsu, M. Nishijima, M. P. Glauser, P. S. Tobias, and R. J. Ulevitch. 1994. CD14 is a

pattern recognition receptor. Immunity 1:509.


Med. 188:2091.


Pugin, J., I. D. Heumann, A. Tomasz, V. V. Kravchenko, Y. Akamatsu, M. Nishijima, M. P. Glauser, P. S. Tobias, and R. J. Ulevitch. 1994. CD14 is a

pattern recognition receptor. Immunity 1:509.


Med. 188:2091.


Pugin, J., I. D. Heumann, A. Tomasz, V. V. Kravchenko, Y. Akamatsu, M. Nishijima, M. P. Glauser, P. S. Tobias, and R. J. Ulevitch. 1994. CD14 is a

pattern recognition receptor. Immunity 1:509.


Med. 188:2091.


Pugin, J., I. D. Heumann, A. Tomasz, V. V. Kravchenko, Y. Akamatsu, M. Nishijima, M. P. Glauser, P. S. Tobias, and R. J. Ulevitch. 1994. CD14 is a

pattern recognition receptor. Immunity 1:509.


Med. 188:2091.


